Neuromodulation therapies already use electrical stimulation to influence brain function. Deep brain stimulation, cortical stimulation and related approaches have been investigated for epilepsy, Parkinson’s disease, depression, traumatic brain injury and memory impairment. Yet the biological mechanisms responsible for their effects in humans have remained difficult to study. Researchers can record brain activity during stimulation, or analyze tissue at the molecular level, but rarely can they examine both processes in the same human neural tissue.

To overcome this limitation, the team developed an ex vivo experimental platform using temporal cortex removed from patients undergoing neurosurgery. The tissue was placed on a microelectrode array, a device containing many tiny electrodes capable of delivering precisely controlled electrical pulses while simultaneously recording neuronal activity. This arrangement allowed the researchers to observe how stimulation reshaped local circuit dynamics in human cortical tissue outside the body, while preserving enough of the tissue’s cellular organization for molecular analysis.

The study focused on cell assemblies, temporary or recurring groups of neurons whose activity becomes coordinated during information processing. Cell assemblies are thought to provide a fundamental mechanism for representing memories, sensory experiences and behavioral states. When neurons within an assembly fire in a coordinated pattern, the circuit can transmit information more reliably than isolated neurons acting independently. The researchers found that electrical stimulation increased the strength of these coordinated assemblies, suggesting that neuromodulation can reinforce functional relationships among neurons rather than simply raising overall activity.

This distinction is important. Brain stimulation is often described as an artificial way to “turn on” neural circuits, but its effects may be more selective and structurally meaningful. By strengthening existing patterns of coordinated activity, stimulation could help stabilize fragile or degraded networks. In conditions such as traumatic brain injury or neurodegenerative disease, memory problems may arise partly because neural populations fail to coordinate effectively. Reinforcing cell assemblies could therefore provide a physiological route through which stimulation improves the encoding or retrieval of information.

The researchers then used single-nucleus genomics to examine the molecular state of individual cells within the stimulated tissue. This method isolates nuclei rather than entire cells and measures gene expression across thousands of nuclei, allowing researchers to determine which genetic programs are active in different cell types. Because the human cortex contains diverse populations of excitatory neurons, inhibitory interneurons and supporting glial cells, single-nucleus analysis can reveal whether stimulation affects all cells equally or engages distinct biological pathways in specific populations.

The results linked the strengthened cell assemblies to cell-type-specific gene regulatory networks. Gene regulatory networks are systems in which transcription factors and other molecular regulators control the activity of groups of genes. These networks influence synaptic plasticity, neuronal excitability, communication between cells and the ability of circuits to adapt. The findings suggest that stimulation-induced changes in coordinated neural activity are not merely transient electrical events. They may also be accompanied by molecular changes that help maintain or refine the altered circuit state.

A major strength of the work was its attempt to test whether the molecular signatures identified in the ex vivo experiments could be observed in the living human brain. The researchers compared their findings with gene-expression patterns associated with in vivo stimulation and identified common cell-type-specific signatures in human cortex. This cross-platform consistency indicates that the effects observed in the laboratory tissue may reflect broader biological responses to neuromodulation, rather than artifacts produced solely by removing tissue from the brain.

The study does not yet establish a clinical treatment or identify a single gene that can be targeted to improve cognition. Instead, it provides a framework for connecting stimulation parameters, circuit physiology and molecular biology. Future therapies could potentially use neural biomarkers to determine when a circuit is poorly coordinated, deliver stimulation at the most effective time and monitor whether the relevant cell assemblies respond. By revealing the genetic programs associated with these responses, the research may also help explain why stimulation benefits some patients more than others and how treatments could be personalized.

The work represents an important step toward a mechanistic science of human neuromodulation. Electrical stimulation has often been developed through trial and error, with clinicians adjusting electrode locations, pulse frequencies and treatment schedules based largely on observed outcomes. The new findings suggest that these variables can eventually be linked to identifiable cell types and gene regulatory networks. Such knowledge could make brain stimulation more precise, more predictable and safer, while opening the possibility of therapies designed not only to activate circuits, but to reshape the biological programs that allow human cognition to recover.

Subject of Research: Human cortical neuromodulation, cell assemblies, gene regulatory networks and cognitive restoration

Article Title: Stimulation modulates gene-linked cell assemblies in the human brain

Article References: Moore, H., Dehnad, M., Freelin, A. et al. Stimulation modulates gene-linked cell assemblies in the human brain. Nature (2026). https://doi.org/10.1038/s41586-026-10879-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-026-10879-9

Keywords: Brain stimulation, neuromodulation, human cortex, temporal cortex, cell assemblies, single-nucleus genomics, gene expression, gene regulatory networks, neural circuits, memory restoration, cognitive function, microelectrode arrays

The investigation focused extensively on postmortem analysis of brain tissue from Parkinson’s patients who had undergone DBS, a surgical intervention commonly employed in managing motor symptoms refractory to medication. While deep brain stimulation targets subcortical structures such as the subthalamic nucleus or the globus pallidus internus to alleviate tremor, rigidity, and bradykinesia, its effects on cortical pathology had remained ambiguous. Researchers meticulously examined multiple regions of the prefrontal cortex, an area pivotal for executive functions, working memory, and decision-making, which are often impaired in PD. Contrary to the prevailing dogma, the researchers observed that Lewy-related pathology was “largely absent” in these prefrontal regions, suggesting a more limited cortical involvement in DBS-treated individuals.

The clinical significance of this discovery lies in the evolving understanding of cognitive impairment in Parkinson’s. Cognitive decline and dementia represent some of the most debilitating aspects of the disease, yet their neuropathological underpinnings have remained elusive. Traditional models have proposed a widespread cortical spread of Lewy bodies as a primary driver of cognitive symptoms. However, this study implies that other mechanisms or pathologies may be responsible for the cognitive decline observed in some PD patients, especially those undergoing neuromodulatory interventions like DBS. This divergence demands a reassessment of how clinicians and researchers approach the non-motor manifestations of Parkinson’s disease.

From a methodological perspective, the research combined advanced immunohistochemical techniques with rigorous neuropathological staging to ensure precise detection of Lewy pathology. Antibodies targeting phosphorylated alpha-synuclein allowed for the visualization of Lewy bodies and neurites with exceptional specificity. Quantitative assessment across different Brodmann areas of the prefrontal cortex provided reliable regional profiles of pathological involvement. Their approach also controlled for confounding factors such as disease duration, medication status, and DBS parameters, thus reinforcing the robustness of the findings.

Interestingly, the absence of Lewy pathology in areas conventionally implicated in executive dysfunction raises the possibility that deep brain stimulation itself may influence the local neuropathological landscape. Whether DBS exerts neuroprotective effects that limit alpha-synuclein aggregation in cortical circuits or whether patients selected for DBS inherently possess distinct pathological phenotypes remains an open question. Future longitudinal studies, potentially including in vivo imaging biomarkers and fluid analyses, could elucidate the temporal dynamics of Lewy pathology in relation to DBS treatment timelines.

This paradigm shift aligns with accumulating evidence suggesting Parkinson’s disease is a heterogeneous syndrome rather than a monolithic entity. Although alpha-synuclein aggregation remains a centerpiece of PD pathology, the distribution, burden, and clinical relevance of Lewy bodies can vary widely between patients. The findings underscore the need for stratified medicine approaches that tailor therapeutic interventions not only to motor symptoms but also to the individualized pathological and clinical phenotypes seen in Parkinson’s disease.

Biochemically, this study calls attention to alternative pathological pathways that might underlie cognitive decline in PD. Tauopathies, amyloid deposition, vascular changes, or neuroinflammatory cascades might contribute more substantially to prefrontal cortical dysfunction than Lewy pathology in some patients. Recognizing these diverse contributors could open new avenues for multimodal diagnostic and therapeutic strategies, integrating biomarker profiles with clinical phenotyping to optimize treatment outcomes.

At a molecular level, the study enhances our understanding of alpha-synuclein’s pathogenic role and encourages reevaluation of its spatial propagation throughout PD. It hints that the widespread cortical Lewy pathology described in classical staging systems (such as Braak staging) may not be a universal feature, especially among patients receiving advanced therapies. This challenges the implementational scope of neuropathological criteria used for diagnosis and prognosis and urges for refined classification schemes that acknowledge such heterogeneity.

The implications extend beyond fundamental neuroscience and clinical neurology into the realm of therapeutic development. Pharmaceutical pipelines targeting alpha-synuclein aggregation could benefit from stratifying trial participants based on the cortical distribution of pathology, as this might influence treatment responsiveness. Furthermore, the functional integrity of prefrontal circuits in DBS-treated patients may differ substantially, necessitating tailored cognitive rehabilitation protocols and monitoring regimens.

Equally significant is the potential impact this research may have on clinical decision-making regarding deep brain stimulation candidacy. Understanding the pathological substrate in DBS recipients can inform expectations about cognitive outcomes and help balance the risks and benefits of surgery. If DBS patients consistently show less cortical Lewy pathology, this might correlate with more preserved cognitive function or modified disease phenotypes, a hypothesis ripe for further clinical studies.

The collective findings invigorate the discourse around the pathophysiology of Parkinson’s disease, invigorating efforts to identify biomarkers predictive of individual pathology patterns. Early detection tools capable of differentiating cortical involvement could revolutionize patient stratification and therapeutic timing, optimizing neuroprotective interventions before irreversible damage ensues.

While the current study focuses on the prefrontal cortex, it calls for broader examinations of other cortical and subcortical structures across different PD subtypes. Comparative analyses with non-DBS Parkinson’s cohorts and Parkinson’s dementia groups could clarify whether the absence of Lewy pathology in the prefrontal cortex is exclusive to DBS patients or reflects wider disease variability. Such comparative neuropathological mapping will be pivotal in deciphering disease mechanisms.

Ultimately, this research heralds a pivotal moment in Parkinson’s disease research, urging the scientific community to rethink entrenched models of Lewy pathology dissemination. The interplay between neuromodulation, pathology, and cognition emerges as a fertile ground for innovation in both basic science and clinical therapeutics. As the field moves forward, integrating these insights will be essential for unlocking new strategies to combat the multifaceted challenges PD presents to patients and their families.

This transformative study, published in npj Parkinson’s Disease, provides a compelling invitation to the neuroscience community to explore new directions in understanding and managing Parkinson’s disease. By illuminating uncharted aspects of cortical pathology in DBS-treated individuals, it charts a course toward more precise, effective, and personalized interventions in this complex neurodegenerative disorder.

Subject of Research: Distribution of Lewy pathology in the prefrontal cortex of Parkinson’s disease patients undergoing deep brain stimulation.

Article Title: Lewy pathology largely absent in prefrontal cortices of Parkinson’s disease patients undergoing deep brain stimulation.

Article References:
Buxbaum Grice, A.S., Kopell, B.H., Laborc, K.F. et al. Lewy pathology largely absent in prefrontal cortices of Parkinson’s disease patients undergoing deep brain stimulation. npj Parkinsons Dis. 12, 152 (2026). https://doi.org/10.1038/s41531-026-01422-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41531-026-01422-8

Deep brain stimulation has revolutionized treatment options for patients with Parkinson’s disease, particularly those experiencing motor fluctuations and medication-refractory symptoms. Traditionally, DBS involves the implantation of electrodes into targeted brain regions such as the STN to deliver electrical impulses that modulate aberrant neuronal activity. Clinically, bilateral STN-DBS—stimulating both hemispheres—is often preferred due to its robust effects on motor symptoms. However, debates have persisted regarding the differential neurophysiological consequences and functional connectivity outcomes produced by unilateral versus bilateral stimulation paradigms, with significant implications for therapy customization.

The study in question employed state-of-the-art neuroimaging and functional network analysis tools to explore these differences with unmatched granularity. By harnessing resting-state functional MRI alongside advanced graph theory metrics, the researchers mapped and compared whole-brain connectivity patterns in patients receiving unilateral versus bilateral STN-DBS. This approach enabled the team to parse out not only local effects at the stimulation sites but also remote influences reflected in large-scale brain networks critical for motor control, cognitive processes, and sensorimotor integration.

One of the landmark findings from the analysis is the pronounced modulation of functional networks implicated in motor and cognitive domains that vary based on the laterality of stimulation. Bilateral STN-DBS led to widespread, bilateral changes in connectivity within sensorimotor circuits, aligning with its demonstrated efficacy in suppressing cardinal motor symptoms like bradykinesia and rigidity. In contrast, unilateral DBS produced more localized connectivity enhancements, predominantly affecting networks contralateral to the side of stimulation. This pattern suggests a more circumscribed neuromodulatory effect potentially coupled with reduced side effects, illuminating a nuanced trade-off between therapeutic breadth and specificity.

Delving deeper into the network dynamics, the study revealed significant alterations in the basal ganglia-thalamocortical loops integral to movement regulation. Bilateral stimulation induced a recalibration of these loops, resulting in enhanced functional integration and synchronization across hemispheres. These changes likely reflect the restoration of more balanced activity within these loops that Parkinson’s disease pathophysiology disrupts. Unilateral stimulation, by contrast, appeared to modulate these circuits asymmetrically, achieving partial normalization with a different profile of network engagement.

Remarkably, cognitive and associative networks also exhibited distinct responses contingent upon stimulation laterality. The bilateral DBS cohort showed modifications in prefrontal and parietal networks, which could influence executive functions and attentional processes. This finding aligns with occasional clinical observations of cognitive side effects following bilateral STN-DBS, underscoring the need for neurofunctional monitoring and tailoring of stimulation parameters. Unilateral stimulation’s impact on these networks was more restrained, potentially offering a favorable cognitive safety profile that merits further exploration.

A particularly innovative aspect of the study lies in its use of network topology measures such as degree centrality and clustering coefficients. These quantifications provided objective markers of how nodes within the brain’s functional architecture reorganize with electrical stimulation. Bilateral stimulation tended to increase global efficiency and network integration, supporting the concept of enhanced communication across disparate brain regions. Conversely, unilateral stimulation maintained higher modularity, preserving more distinct network communities, which may correspond to differential clinical outcomes.

Furthermore, the analysis of interhemispheric connectivity exposed subtle but significant dissimilarities. Bilateral STN-DBS promoted stronger homotopic functional coupling between hemispheres, potentially restoring symmetry disrupted in Parkinson’s disease. Unilateral stimulation did not elicit this effect to the same extent, emphasizing how laterality of electrode placement influences not only local but also remote neurophysiological processes. These nuances highlight the complexity of DBS mechanisms beyond simple linear models of stimulation effects.

The temporal dynamics of DBS-induced network changes also emerged as a critical consideration. The study suggested that the onset and durability of network reorganization differ between unilateral and bilateral stimulation. Bilateral DBS seemed to accomplish rapid and sustained network integration shifts, whereas unilateral DBS brought about more gradual or transient effects. This temporal dimension may relate to variability in clinical symptom relief trajectories and informs strategies for programming and longitudinal monitoring.

This research holds profound clinical implications for personalized medicine in Parkinson’s disease management. The capacity to predict how unilateral versus bilateral stimulation will modulate an individual’s functional brain networks opens avenues for tailoring DBS approaches that maximize benefit while minimizing cognitive and neuropsychiatric side effects. Particularly for patients with asymmetric symptom profiles or cognitive vulnerabilities, unilateral STN-DBS might represent a balanced compromise pending corroborative studies.

Importantly, the findings challenge the conventional notion that bilateral stimulation is invariably superior, suggesting that the choice of unilateral versus bilateral STN-DBS should consider detailed functional network consequences beyond symptomatic profiles alone. This study provides a compelling argument for integrating multimodal neuroimaging and network neuroscience techniques into clinical decision-making frameworks for DBS therapy customization.

The authors acknowledge certain limitations, including sample size and inter-individual variability, which warrant cautious extrapolation. They advocate for longitudinal and larger cohort studies integrating clinical, neuroimaging, and electrophysiological data to further unravel the multifaceted neurobiology underlying DBS effects. Future work could also explore how stimulation parameters—pulse width, frequency, amplitude—influence functional network modifiability.

In sum, this pivotal study enriches our understanding of the brain-wide network effects elicited by unilateral and bilateral deep brain stimulation of the subthalamic nucleus. It delineates fundamental differences in functional connectivity profiles that underpin the disparate clinical outcomes observed with these approaches. By leveraging the tools of network neuroscience and advanced neuroimaging, it paints a more sophisticated picture of DBS as not merely a focal intervention but a broad modulator of distributed brain systems.

As DBS technologies evolve—encompassing adaptive stimulation and closed-loop paradigms—such mechanistic insights become indispensable. They enable clinicians and researchers to refine stimulation strategies informed by objective biomarkers of brain function. Consequently, this work sets the stage for accelerating the transition toward truly personalized neuromodulation therapies that optimize both motor and cognitive outcomes for individuals with Parkinson’s disease.

Ultimately, this research underscores that the future of DBS lies in harnessing the brain’s intrinsic connectivity architecture. Understanding how unilateral and bilateral stimulation differentially recalibrate these dynamic networks will catalyze innovations that enhance therapeutic precision and patient quality of life. This landmark contribution represents a paradigm shift in how we conceptualize and implement deep brain stimulation interventions for neurodegenerative disorders.

Subject of Research: Functional network differences induced by unilateral versus bilateral deep brain stimulation of the subthalamic nucleus in Parkinson’s disease patients.

Article Title: Functional network differences between unilateral and bilateral deep brain stimulation of the subthalamic nucleus.

Article References:
Santyr, B., Boutet, A., Abbass, M. et al. Functional network differences between unilateral and bilateral deep brain stimulation of the subthalamic nucleus. npj Parkinsons Dis. 11, 215 (2025). https://doi.org/10.1038/s41531-025-01064-2

Image Credits: AI Generated